Authors
Laísa Macedo Tavares, Luís Cláudio Lima de Jesus, Viviane Lima Batista, Fernanda Alvarenga Lima Barroso, Andria Dos Santos Freitas, Gabriela Munis Campos, Monique Ferrary Américo, Tales Fernando da Silva, Nina Dias Coelho-Rocha, Giovanna Angeli Belo, Mariana Martins Drumond, Pamela Mancha-Agresti, Kátia Duarte Vital, Simone Odília Antunes Fernandes, Valbert Nascimento Cardoso, Alexander Birbrair, Enio Ferreira, Flaviano Santos Martins, Juliana Guimarães Laguna, Vasco Azevedo
Published in
World journal of microbiology & biotechnology. Volume 39. Issue 9. Pages 235. Jun 27, 2023. Epub Jun 27, 2023.
Abstract
Intestinal mucositis is a commonly reported side effect in oncology patients undergoing chemotherapy and radiotherapy. Probiotics, prebiotics, and synbiotics have been investigated as alternative therapeutic approaches against intestinal mucositis due to their well-known anti-inflammatory properties and health benefits to the host. Previous studies showed that the potential probiotic Lactobacillus delbrueckii CIDCA 133 and the prebiotic Fructooligosaccharides (FOS) alleviated the 5-Fluorouracil (5-FU) chemotherapy-induced intestinal mucosa damage. Based on these previous beneficial effects, this work evaluated the anti-inflammatory property of the synbiotic formulation containing L. delbrueckii CIDCA 133 and FOS in mice intestinal mucosa inflammation induced by 5-FU. This work showed that the synbiotic formulation was able to modulate inflammatory parameters, including reduction of cellular inflammatory infiltration, gene expression downregulation of Tlr2, Nfkb1, and Tnf, and upregulation of the immunoregulatory Il10 cytokine, thus protecting the intestinal mucosa from epithelial damage caused by the 5-FU. The synbiotic also improved the epithelial barrier function by upregulating mRNA transcript levels of the short chain fatty acid (SCFA)-associated GPR43 receptor and the occludin tight junction protein, with the subsequent reduction of paracellular intestinal permeability. The data obtained showed that this synbiotic formulation could be a promising adjuvant treatment to be explored against inflammatory damage caused by 5-FU chemotherapy.
PMID:
37365380
Bibliographic data and abstract were imported from PubMed on 16 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0